Related Party - Gilead Sciences, Inc. - Additional Information (Details) $ / shares in Units, shares in Millions	1 Months Ended				3 Months Ended		12 Months Ended
	Jan. 31, 2024 USD ($) shares	Jun. 30, 2023 USD ($) Program shares	May 31, 2023 USD ($) Program	Jul. 31, 2020 USD ($)	Mar. 31, 2024 USD ($) $ / shares	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 Program	Dec. 31, 2020 USD ($)
Related Party Transaction [Line Items]
Common stock share value					$ 228,000,000
Related Party
Related Party Transaction [Line Items]
Percentage of outstanding common stock held					33.10%
Related Party | Research and Development
Related Party Transaction [Line Items]
Reimbursement from related party for shared costs					$ 16,000,000	$ 33,000,000
Purchase Agreement | Related Party
Related Party Transaction [Line Items]
Common stock shares issued | shares	15.2	1.0
Common stock share value		$ 20,000,000
Funds received for stock purchase agreement	$ 320,000,000
Purchase price of common stock allocation to performance obligation	$ 87,000,000
Percentage of premium purchase price of common stock					20.00%
Trailing days average closing price					5 days
Weighted average closing price of our common stock on grant date (in dollars per share) | $ / shares					$ 33.54
Purchase Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Right to purchase additional outstanding voting common stock percentage					35.00%
Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Option payment upon completion of certain IND-enabling activities							$ 60,000,000
Option payment upon achievement of certain development milestones							150,000,000
Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Collaboration term for current and future clinical programs									10 years
Option continuation payment due upon sixth anniversary of agreement									$ 100,000,000
Upfront cash payment				$ 175,000,000
Option fee per program for all other programs entering clinical development to exercise option							$ 150,000,000
Number of research programs							2
Revenue recognized					$ 141,000,000	$ 25,000,000
Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Potential regulatory approval milestones payment receivable related to domvanalimab							$ 500,000,000
Amended Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Number of exercise option to programs | Program								3
Option payments received							725,000,000
Removal of option continuation payment under agreement							$ 100,000,000
Option payment upon achievement of certain development milestones			$ 150,000,000
Number of programs, eligible to receive regulatory and commercial milestone payments | Program			2
Amended Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Upfront cash payment		$ 35,000,000	$ 17,500,000
Number of research programs | Program		2
Option payment upon completion of certain IND-enabling activities			45,000,000
Amended Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Regulatory and commercial milestone payments received			$ 375,000,000